Search | Clinical Trials Finder

Conditions: Atherosclerosis, Kidney Failure
Interventions: tacrolimus, mycophenolate mofetil, prednisone, sirolimus; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF; Procedure · Drug · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Transplant; Complications, Drug Interaction Food
Interventions: Grapefruit Juice; Dietary Supplement
Lead sponsor: Shirley M. Tsunoda; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Liver Transplant Recipient
Interventions: Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Everolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Corticosteroids; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 10 more

Conditions: Sarcoma
Interventions: F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, melphalan, prednisone, sirolimus, tacrolimus, vincristine sulfate, peripheral blood stem cell transplantation, Filgrastim, Peripheral Blood Stem Cell donation; Drug · Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Interventions: FLUDARABINE, CAMPATH-IH, Total Body Irradiation, FK506, G-SCF (Granulocyte-colony stimulating factor); Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: End Stage Renal Disease
Interventions: Mycophenolate Sodium Delayed Release Tablets, Mycophenolate Mofetil; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions: Orca-T, Standard-of-Care; Biological
Lead sponsor: Orca Biosystems, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 14 more

Conditions: Liver Transplantation
Interventions: Tacrolimus Withdrawal and Everolimus Monotherapy; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplant
Interventions: Sirolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, sargramostim, busulfan, fludarabine phosphate, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lymphoma
Interventions: Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX); Procedure · Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 19
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more

Conditions: Uterine Factor Infertility
Interventions: Uterine Allotransplantation, Tacrolimus, Imuran; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2043
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: BK Viremia, BK Nephropathy
Interventions: Tacrolimus, Mycophenolate acid, Sirolimus; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: New York, New York

Conditions: Pediatric Recipients of a Liver Transplant
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 1 Year to 18 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • New York, New York + 2 more

Conditions: Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Fludarabine, Itacitinib Adipate, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sirolimus, Tacrolimus; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine, Busulfan, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Pharmacological Study, Tacrolimus; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 74 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 17
States / cities: Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more

Conditions: High Risk Myeloid Malignancies, Cord Blood Transplant
Interventions: ECT-001-CB (UM171-Expanded Cord Blood Transplant); Biological
Lead sponsor: ExCellThera inc.; Industry
Eligibility: 0 Years to 21 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Allogeneic islets of Langerhans transplant; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Renal Transplantation
Interventions: sotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Ann Arbor, Michigan + 3 more

Conditions: Uveitis
Interventions: fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 13 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 21
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Renal Transplantation
Interventions: TCD601, belatacept, ATG, TAC, MPA, Corticosteroids; Biological · Drug
Lead sponsor: ITB-Med LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Sacramento, California • San Francisco, California • Tampa, Florida + 15 more

Conditions: End Stage Liver Disease, Hepatitis C
Interventions: Daclizumub, Tacrolimus, Cyclosporine, MMF; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions: Efprezimod alfa, Methotrexate, Tacrolimus, Placebo; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Search by objective public record fields.

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

Cord Blood Expansion on Mesenchymal Stem Cells

Drug Interaction With Envarsus XR and Grapefruit Juice

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Myfortic vs. Cellcept in Kidney Transplant Recipients

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation

The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Uterus Transplantation to Treat Infertility

Using mTOR Inhibitors in the Prevention of BK Nephropathy

Medication Adherence in Children Who Had a Liver Transplant

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients

Multicenter Uveitis Steroid Treatment (MUST) Trial

A Study of TCD601 in de Novo Renal Transplant Recipients

Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)